Endonovo Therapeutics (OTCMKTS:ENDV) and Zynex (NASDAQ:ZYXI) Financial Comparison

Zynex (NASDAQ:ZYXI) and Endonovo Therapeutics (OTCMKTS:ENDV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.

Risk & Volatility

Zynex has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, Endonovo Therapeutics has a beta of -1.74, indicating that its stock price is 274% less volatile than the S&P 500.

Valuation and Earnings

This table compares Zynex and Endonovo Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zynex	$184.32 million	1.29	$9.73 million	$0.15	49.87
Endonovo Therapeutics	$140,000.00	1.04	$6.93 million	N/A	N/A

Zynex has higher revenue and earnings than Endonovo Therapeutics.

Insider & Institutional Ownership

29.7% of Zynex shares are owned by institutional investors. 52.1% of Zynex shares are owned by company insiders. Comparatively, 5.6% of Endonovo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Zynex and Endonovo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zynex	2.49%	13.05%	3.78%
Endonovo Therapeutics	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and price targets for Zynex and Endonovo Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zynex	0	0	2	0	3.00
Endonovo Therapeutics	0	0	0	0	0.00

Zynex currently has a consensus price target of $14.00, indicating a potential upside of 87.17%. Given Zynex’s stronger consensus rating and higher probable upside, research analysts clearly believe Zynex is more favorable than Endonovo Therapeutics.

Summary

Zynex beats Endonovo Therapeutics on 12 of the 12 factors compared between the two stocks.

About Zynex

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

About Endonovo Therapeutics

Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.